A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of ETC-1002 Versus Placebo in Patients With Hypercholesterolemia Receiving Ongoing Statin Therapy

Trial Profile

A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of ETC-1002 Versus Placebo in Patients With Hypercholesterolemia Receiving Ongoing Statin Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Bempedoic acid (Primary) ; HMG-CoA reductase inhibitors
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Apr 2016 Results assessing the effect of ETC-1002 on serum low-density lipoprotein cholesterol published in the American Journal of Cardiology
    • 04 Nov 2015 According to an Esperion Therapeutics media release, full results from this study will be presented at the American Heart Association (AHA) Scientific Sessions 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top